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MaOBJECTIVES The aim of this study was to describe the incidence and clinical characteristics, including intracoronary
imaging features, of clinical restenosis in bioresorbable coronary scaffolds (BRS). Further, the authors searched for
clinical and procedural predictors of scaffold restenosis (ScR) and report on the clinical outcomes after treatment of ScR
in a cohort of consecutive all-comer patients.
BACKGROUND Data from randomized controlled trials demonstrate a higher rate of target lesion failure in
patients treated with BRS as compared with those treated with metal drug-eluting stents. Although in-scaffold
thrombosis has been thoroughly investigated, there are little data available on the incidence and characteristics of ScR.
METHODS A total of 657 consecutive patients (age 63  12 years, 79% men, 21% diabetics, 67% acute coronary
syndrome) who received a total of 883 BRS for the treatment of coronary artery stenoses between May 2012 and January
2015 were enrolled in a retrospective registry.
RESULTS During the median follow-up of 1,076 days (interquartile range: 762 to 1,206 days), a total of 49 cases of ScR
were found in 41 patients (Kaplan-Meier incidence: 2.4%, 6.0%, and 9.0% at 12-, 24-, and 36-month follow-up,
respectively). ScR presented as stable angina or as incidental finding in 73% of the cases. The angiographic pattern was
complex (type II to IV) in 55% of the ScR lesions. The neointima was homogeneous with high signal intensity in all but
3 cases at optical coherence tomography. Prior revascularization (hazard ratio [HR]: 2.7; 95% confidence interval [CI]:
1.5 to 5.1; p ¼ 0.002), diabetes (HR: 2.9; 95%CI: 1.5 to 5.4; p ¼ 0.001), lesion types B2 or C (HR: 2.8; 95% CI: 1.5 to 5.4;
p ¼ 0.002), and implantation technique (HR: 0.3; 95% CI: 0.1 to 0.6; p ¼ 0.001) emerged as independent predictors of
ScR. Oversizing (HR: 6.29; 95% CI: 2.4 to 16.4), undersizing (HR: 5.15; 95% CI: 1.99 to 13.30), and a residual stenosis
>27% (HR: 8.9; 95% CI: 3.6 to 21.8) were associated with an increased ScR risk.
CONCLUSIONS The 3-year incidence of ScR was similar to that observed in similar settings with newer-generation
drug-eluting stents. It is often associated with a benign presentation and a complex angiographic pattern. Predictors
of ScR match those of metallic stent restenosis, and the implantation technique used at index appears to play an
important role. (J Am Coll Cardiol Intv 2017;10:1819–27) © 2017 by the American College of Cardiology Foundation.m the aKardiologie I, Zentrum für Kardiologie, University Medical Center Mainz and Deutsches Zentrum für Herz und Kreislauf
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ABBR EV I A T I ON S
AND ACRONYMS
BRS = bioresorbable coronary
scaffold
CI = confidence interval
HR = hazard ratio
IQR = interquartile range
MLD = minimal lumen diameter
OCT = optical coherence
tomography
QCA = quantitative coronary
angiography
RVD = reference vessel
diameter
ScR = scaffold restenosis
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1820R ecent data from randomizedcontrolled trials and meta-analyseswith long-term follow-up reported
increased rates of target lesion failure after
implantation of coronary bioresorbable coro-
nary scaffolds (BRS) as compared with
metallic drug-eluting stents (1–4). Given its
high impact in terms of mortality and
morbidity, a major focus has been placed on
the pathophysiology of scaffold thrombosis,
whereas much less evidence is available to
date regarding the incidence of scaffold
restenosis (ScR). As well, little data exist on
the clinical presentation and possible mecha-
nisms of this additional complication of BRS.A para
ve
Post-p
SEE PAGE 1828Possibly due to the larger strut thickness, imaging
studies have demonstrated that the implantation of
BRS is associated with fewer uncovered struts and a
thicker neointimal coverage compared with drug-
eluting stents (5,6). Although this has been inter-
preted as a positive healing phenomenon in the
setting of unstable plaques, neointimal proliferation
may also lead to an increased risk of restenosis and
concur to the incidence of device failure. In line with
this, the 3-year data of the ABSORB II study showed
a larger mean change in minimal lumen area from
post-procedure in the scaffold group as compared
with the drug-eluting stent group (p ¼ 0.04),
resulting in a larger incidence of binary in-device
restenosis (7.0% vs. 0.7%; p ¼ 0.003) (1). In
contrast, in the recent AIDA (Amsterdam Investi-
gator-Initiated Absorb Strategy All-Comers Trial)
trial, the 2-year incidence of ScR was 4.1%, similar
(p ¼ 0.53) to that recorded in drug-eluting stents
(4.6%; hazard ratio [HR]: 0.87; 95% confidence
interval [CI]: 0.55 to 1.36) (2).
The incidence of ScR in more complex all-comers
settings has not been reported yet. As well, it
remains to be investigated whether clinical and
procedural factors may influence the incidence of
ScR, and whether this risk can be addressed at
the time of implantation.
METHODS
The study belongs to the MICAT (Mainz Intracoronary
daTabase) project (NCT02180178), which is approved
by the ethics committee of the Landesärztekammer
Mainz.
PATIENTS AND DEFINITIONS. Clinical characteristics
and quantitative coronary angiography (QCA) data ofall consecutive patients treated with a BRS (Absorb
1.1, Abbott Vascular, Santa Clara, California) between
May 2012 and January 2015 in our institution were
collected in a retrospective registry. Patient data were
treated anonymously. Bypass grafts and in-stent
restenoses were not treated with BRS, and implanta-
tion of BRS in calcific or tortuous vessels, in bi-
furcations with side branch >2 mm, and in ostial
lesions (starting January 1, 2014) was also discour-
aged. Overlap between BRS was minimized. Dual
antiplatelet therapy (with prasugrel or ticagrelor
for acute coronary syndrome patients) was recom-
mended for 12 months in all.
Follow-up was obtained by trained personnel using
standardized methods (7). Clinical restenosis was
defined as the presence of symptoms or functional
evidence of ischemia and a diameter stenosis >50% as
assessed in the local core laboratory or the presence
of at least 70% diameter stenosis in the BRS or the
5 mm at the proximal or distal edge (8). The differ-
ential diagnosis with BRS thrombosis was based on
clinical presentation or angiographic or imaging
evidence of device thrombosis.
The outcome of patients treated using an implan-
tation protocol designed to specifically address the
issue of incomplete BRS expansion was compared
with that of patients treated with a standard
implantation technique. The “optimal implantation
technique” included 1:1 pre- and post-dilatation with
a noncompliant balloon, appropriate sizing (<15%
deviation from the QCA reference vessel diameter
[RVD]), RVD between the available nominal BRS sizes
(2.5 to 3.5 mm), and achievement of a final residual
stenosis <20%.
QCA AND OPTICAL COHERENCE TOMOGRAPHY
ANALYSIS. A list of the methods, definitions, mea-
surements performed, and local reproducibility has
been previously published (7,9,10). Briefly, the key
QCA parameters (Xcelera, Philips, Amsterdam, the
Netherlands) included the in-BRS minimal lumen
diameter (MLD), the final RVD, and the following




rocedural in-scaffold residual stenosis calculatedas:
In-scaffold residual stenosis ¼ 100$RVDMLD
RVD
ical coherence tomography (OCT) features ofOpt
ScR were collected at the time of the event to









(n ¼ 41) p Value
Age, yrs 63  12 63  12 64  11 0.54
Male 531 (79) 497 (79) 34 (83) 0.42
Hypertension 489 (73) 458 (72) 31 (76) 0.76
Diabetes 144 (22) 126 (20) 18 (44) <0.001
Smoking 277 (42) 266 (42) 11 (27) 0.06
Family history of CAD 142 (21) 138 (22) 4 (10) 0.07
Hyperlipidemia 274 (41) 253 (40) 21 (51) 0.12
Prior CABG 14 (2) 13 (2) 1 (2) 0.98
Prior PCI 186 (28) 166 (26) 20 (49) 0.004
Prior stroke/TIA 27 (4) 24 (4) 3 (7) 0.28
LVEF, % 52  9 52  9 52  9 0.29
Silent/stable angina 280 (37) 251 (35) 29 (48) 0.06
Unstable angina 87 (11) 79 (11) 8 (13) 0.62
NSTEMI 212 (27) 196 (28) 16 (27) 0.99
STEMI 177 (23) 170 (24) 7 (12) 0.02
BRS per patient 1.4  0.8 1.4  0.8 1.8  1.1 0.017
Hybrid BVSþDES 342 (53) 319 (53) 23 (50) 0.62
LM treated with BRS 0 (0) 0 (0) 0 (0) 1.00
LAD treated with BRS 339 (44) 313 (44) 26 (43) 0.80
LCX treated with BRS 191 (25) 179 (25) 12 (20) 0.52
RCA treated with BRS 233 (31) 211 (30) 22 (37) 0.38
Graft treated with BRS 1 (0,1) 1 (0,1) 0 (0) 0.97
Ostial lesion 61 (8) 54 (8) 7 (12) 0.55
AHA lesion type B2 or C 322 (42) 285 (41) 37 (62) <0.001
CTO 21 (3) 14 (2) 7 (12) <0.001
Pre-dilatation 752 (99) 696 (99) 56 (93) 0.22
Minimum stent diameter, mm 2.90  0.47 2.97  0.44 2.84  0.34 0.002
Total length BVS per patient, mm 27  18 27  19 34  14 <0.001
Post-dilatation 365 (48) 340 (49) 25 (42) 0.87
Overlap 92 (13) 81 (12) 11 (22) 0.02
Bifurcation 92 (14) 88 (14) 4 (9) 0.28
Clopidogrel 168 (42) 150 (26) 18 (37) 0.03
Prasugrel 265 (42) 248 (43) 17 (35) 0.51
Ticagrelor 112 (18) 109 (19) 3 (6) 0.06
Values are mean  SD or n (%).
AHA¼ American Heart Association; BRS¼ bioresorbable coronary scaffold; BVS¼ bioresorbable
vascular scaffold; CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; CTO ¼
chronic total occlusion; DES ¼ drug-eluting stent(s); eGFR ¼ estimated glomerular filtration rate;
LAD ¼ left anterior descending artery; LCX ¼ left circumflex artery; LM ¼ left main; LVEF ¼ left
ventricular ejection fraction; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼
percutaneous coronary intervention; RCA ¼ right coronary artery; ScR ¼ in-scaffold restenosis;
STEMI ¼ ST-segment elevation myocardial infarction; TIA ¼ transient ischemic attack.
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1821provide a descriptive analysis of the presence of
malapposition, strut fracture, scaffold size, and tissue
characteristics; see the Online Appendix as well as
Gori et al. (11) for definitions and reproducibility of
the measurements. Images were acquired with the
C7XR imaging console and Dragonfly imaging cath-
eter (Optis, St. Jude Medical, St. Paul, Minnesota)
and analyzed offline with the QCU-CMS software
Version 4.69 (Leiden University, Leiden, the
Netherlands). The neointima was characterized based
on the intensity (homogeneous vs. nonhomogeneous)
and the smoothness of the luminal borders. Homo-
geneous neointima showed uniform signal properties
without focal variation or attenuation. Heteroge-
neous neointima presented as a layered pattern with
an endoluminal high backscattering layer and an
abluminal low-backscattering layer (12).
STATISTICAL ANALYSIS. Continuous variables are
presented as mean  SD or median (interquartile
range [IQR]) based on the inspection of the Q-Q plots.
Accordingly, they were compared using a Student
unpaired t test, Mann-Whitney U test, Kruskal-Wallis
test, or analysis of variance. Categorical variables are
presented as counts and percentages, and were
compared using the Fisher exact test. Kaplan-Meier
analysis was used to derive the event rates and plot
time-to-event curves. Cox proportional hazards
analysis was performed to identify the clinical and
procedural parameters relevant for ScR. Potential
covariates were prioritized a priori for data analysis
with an approximately 1:10 covariate-to-case ratio to
minimize overmodeling (13). Potential covariates
were chosen based on a review of literature on drug-
eluting stent restenosis and included diabetes, prior
revascularization, treatment of complex lesions
(American Heart Association lesion type B2 or C) at
index, implantation technique (including procedural
parameters as well as parameters of vessel size, BRS
sizing, and BRS or vessel expansion). Univariate and
multivariable HRs and 95% CIs are reported accord-
ingly. The hypothesis that both undersizing and
oversizing (nominal or RVD ratio) and a larger percent
residual stenosis might be associated with increased
restenosis risk was investigated for possible dichot-
omization by inspection at 0.1-percentile intervals. A
generalized estimating equation model was used to
evaluate the differences in the QCA parameters (MLD,
RVD, and % stenosis) with consideration of correla-
tion structure (multiple lesions per patient). Statisti-
cal analyses were performed with MedCalc version 9
(MedCalc Software, Mariakerke, Belgium) and R
Statistical Software (R Foundation for Statistical
Computing, Vienna, Austria).RESULTS
A total of 657 patients (mean age 63  12 years, 79%
men, 22% diabetic, 63% acute coronary syndrome)
who received a total of 883 BRS (1.4  0.8 per patient)
were included. The median follow-up was 1,076 days
(IQR: 762 to 1,206 days), with a 3-year follow-up in
386 of 416 (93%) patients who had reached 3 years at
the time of the last follow-up; a 2-year follow-up was
available in 586 (89%) patients.
The clinical and procedural characteristics of the
patients with or without ScR are presented in Table 1.
FIGURE 1 Incidence of ScR and Clinical Presentation of Patients With ScR
There was no clear pattern in the clinical presentation over time. *Incidental finding in the
presence of another culprit lesion. §Incidental finding in 1 case. KM ¼ Kaplan-Meier;
NSTEMI ¼ non–ST-segment elevation myocardial infarction; ScR ¼ scaffold restenosis;
St ¼ stable; STEMI ¼ ST-segment elevation myocardial infarction; Unst ¼ unstable.






(n ¼ 49) p Value
Pre-procedural MLD, mm 0.59  0.51 0.60  0.50 0.310
Pre-procedural RVD, mm 2.99  0.61 2.44  0.84 <0.001
Stenosis, % 79.5  17.4 71.9  18.6 0.012
Post-procedural MLD, mm 2.58  0.43 2.05  0.51 <0.001
Post-procedural RVD, mm 2.98  0.45 2.79  0.51 0.014
Residual stenosis 14.0  10.5 26.0  15.9 <0.001
Values are mean  SD.
MLD ¼ minimal lumen diameter; RVD ¼ reference vessel diameter; ScR ¼
in-scaffold restenosis.
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1822Figure 1 depicts the Kaplan-Meier curve for the inci-
dence of ScR and the corresponding clinical presen-
tation. A total of 49 ScRs were recorded in 41 patients.
The Kaplan-Meier incidence of ScR was 2.4% at
12 months, 6% at 2 years, and 9% at 3 years. The most
frequent presentation included stable angina (n ¼ 15)
or incidental diagnosis in asymptomatic patients
(n ¼ 11) or in patients with ST-segment elevation
myocardial infarction with the culprit lesion in a
separate vessel (n ¼ 4). ScR presented as non–ST-
segment elevation myocardial infarction in 4 patients
and unstable angina in another 4. In 2 patients (1 with
unstable angina and 1 with non–ST-segment elevation
myocardial infarction), a type Ib ScR was an inci-
dental finding as symptoms were likely driven by
thrombosis in another scaffold. The differential
diagnosis of ScR versus in-BRS thrombosis was
confirmed in these cases by OCT. In sum, ScR pre-
sented as acute coronary syndrome only in 8 of
41 patients.
Patients with ScR had more frequently diabetes
(44% vs. 20%; p < 0.001), prior percutaneous revas-
cularization (49% vs. 26%; p ¼ 0.004), complex ste-
noses (62% vs. 41% for B2 or C lesions and 12% vs. 2%
for chronic total occlusions; both p < 0.001). The totalimplanted length was larger (34  14 mm vs. 27 
19 mm; p < 0.001) and the minimum stent diameter
smaller (2.84  0.34 mm vs. 2.97  0.44 mm;
p ¼ 0.002) in ScR patients. The QCA characteristics
at index are presented in Table 2. Features of patients
with ScR included a smaller RVD, a smaller post-
procedural MLD, and a larger residual stenosis (all
p < 0.001).
ANGIOGRAPHIC AND OCT CHARACTERISTICS OF ScR.
Data are presented in Figures 2 and 3 and Online
Table S1. At angiography, 22 restenoses were focal
(type Ib, margin, n ¼ 10; and type Ic, focal body,
n ¼ 12), 13 were diffuse intrastent (type II), 5 were
proliferative (type III), and 9 were total occlusions.
OCT movies were available in 27 lesions (n ¼ 24) with
ScR and are compared in Online Table S2 with those
of 115 lesions (115 patients) who underwent elective
OCT. Scaffolds and lumen diameters or areas were
consistently smaller in ScR lesions (all p < 0.001). The
neointima was mostly homogeneous and presented a
high intensity (n ¼ 23). An inhomogeneous neointima
with low-intensity areas was present in only 4 cases.
In 1 case, ScR was likely caused by BRS fracture and
subsequent formation of an endothelial bridge be-
tween originally noncontiguous struts. There was no
case of neoatherosclerosis. Fractures were signifi-
cantly more frequent in ScR lesions as compared with
control OCTs (60.8% vs. 34.8%; p ¼ 0.03). Malap-
posed struts and evaginations were a rare finding in
ScR lesions (n ¼ 1 and n ¼ 4, respectively; p ¼ 0.016
and p ¼ 0.019 compared with control OCT).
TREATMENT OF ScR AND OUTCOME AFTER TREATMENT.
ScR lesions (n ¼ 49) were treated with implantation of
a drug-eluting stent in 33 cases, with percutaneous
transluminal coronary angioplasty only or percuta-
neous transluminal coronary angioplasty with a drug-
eluting balloon (n ¼ 4 for both, all occurring within
6 months of implantation), with another BRS in 1
case, and with surgery in another 1 in which multiple
FIGURE 2 Angiographic and OCT Patterns of Restenosis
Left panels show types of angiographic restenosis. The right panels show types of neointima at optical coherence tomography (OCT): (A) high
intensity, homogeneous with smooth borders; (B) with evidence of low-intensity areas (asterisk). Stent struts are marked with S or S’
(overlap).
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1823other de novo lesions were present. In 6 patients or
lesions (full occlusions) a therapy was not possible.
Follow-up was available in all patients at 545
(IQR: 168 to 866) days after the diagnosis of ScR. One
patient died at home 14 days after drug-eluting
balloon treatment of a type 2 restenosis, which pre-
sented at 152 days after implant. The patient had been
on treatment with prasugrel since the index proced-
ure. No other event was reported.
PREDICTORS OF ScR. The full results of the univar-
iate Cox regression analysis, including pre-specified
and non–pre-specified variables, are presented in
Online Table S2. The results of the multivariable
analysis are presented in Table 3: prior revasculari-
zation (HR: 2.72), diabetes (HR: 2.89), treatment of B2
or C lesions (HR: 2.81), and implantation technique
(HR: 0.30) were all independent predictors of ScR.
The model p value was <0.001, the receiver-operating
characteristic c-statistic was 0.76.
Both BRS oversizing (nominal BRS diameter or RVD
>1.13; i.e., choice of a BRS 13% larger than the vesseldiameter) and undersizing (nominal or RVD
ratio <0.91; i.e., choice of a BRS 9% smaller than the
reference vessel) were associated with an increased
incidence of ScR (HR: 6.29; 95% CI: 2.40 to 16.40;
and HR: 5.15; 95% CI: 1.99 to 13.30, respectively)
(Central Illustration). Intermediate degrees of under-
and oversizing showed a linear relationship between
missizing and risk of ScR. In line with the concept
that oversizing might be a predictor of ScR, a $10%
increase in RVD from baseline to final after implan-
tation was also associated with an increased risk of
ScR (HR: 2.03; 95% CI: 1.12 to 3.67; p ¼ 0.0196).
The incidence of ScR increased with increasing
degree of residual stenosis beyond 27% HR: 8.86; 95%
CI: 3.60 to 21.81; p < 0.0001). On receiver-operating
characteristic analysis, a residual stenosis >27% was
associated with a sensitivity and specificity of 53%
and 91% in the prediction of ScR, respectively. The
area under the receiver-operating characteristic curve
was 0.736. Finally, the incidence of ScR was higher for
RVDs smaller than 2.7 mm and further increased
below 2.57 mm (Central Illustration).
TABLE 3 Independent Correlates of ScR
p Value HR 95% CI
Prior revascularization 0.0017 2.7211 1.4593–5.0740
Diabetes 0.0009 2.8907 1.5491–5.3941
AHA lesion type B2/C 0.0020 2.8062 1.4651–5.3749
Implantation technique 0.0014 0.2975 0.1420–0.6232
AHA ¼ American Heart Association; CI ¼ confidence interval; HR ¼ hazard ratio;
ScR ¼ scaffold restenosis.
FIGURE 3 Angiographic and Optical Coherence Tomography Appearance
of the Restenosis
Left panel shows angiographic appearance of restenosis. Right panel shows optical
coherence tomography appearance of the restenosis.
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1824DISCUSSION
Despite significant progress with drug-eluting tech-
nologies, in-stent restenosis remains 1 of the limiting
factors for the success of coronary stent implantation,
and an important challenge for new technologies (14).
The pathophysiology of this phenomenon is multi-
factorial and comprises patient-related factors (e.g.,
diabetes and a history of restenosis), procedure-
related factors (number and size of stents used,
stent overlap, percent residual stenosis), and lesion-
related factors (small vessel size, American Heart
Association or American College of Cardiology lesion
complexity including features such as chronic total
occlusion, ostial lesions, long lesions, and calcific le-
sions) (15–17).
We extend these notions from metallic stents to
BRS. The main findings of the present study include
the following. First, despite the complexity of the
lesions, the 3-year incidence of ScR in a series of
consecutive patients was similar to that observed in
similar settings with newer-generation drug-eluting
stents; ScR had mostly (three-quarters of the cases) a
benign presentation. Second, the angiographic
appearance of ScR is complex (type II to IV) in a sig-
nificant fraction of ScRs, and, confirming previous
case reports (18), the neointima appears to be mostly
mature and compatible with fibrotic tissue at OCT.
Evidence compatible with neoatherosclerosis was not
found. Third, the predictors of ScR are similar to
those known for metallic stents and include diabetes,
treatment of complex lesions, and prior intervention.
Similar to scaffold thrombosis (7), the technique used
at the time of implantation has a central role in
reducing the incidence of ScR. Last, both BRS over-
sizing and undersizing, as well as vessel size andresidual stenosis at index, are associated with an
increased risk of ScR.
POSSIBLE MECHANISMS OF ScR. Initial data from
serial analyses of BRS reported a tissue response
quantitatively similar to that following implantation
of newer-generation stents (19). Later analyses based
on computational fluid dynamics techniques (20);
however, demonstrated that the thick protruded
struts of the BRS cause proximal and distal blood flow
disturbance and recirculation microenvironments,
resulting in areas of low blood wall shear stress,
which stimulate neointima formation. Oversizing of
the implanted device may amplify this phenomenon
through 2 mechanisms: first, the increased strut
density increases recirculation areas; second, the
vessel wall injury is also a well-known stimulus for
neointima proliferation. The existence of a possible
relationship between stent oversizing and risk of
restenosis has long been disputed for metallic devices
(21). The present data appear to confirm the existence
of such a relationship with BRS.
The possible role of undersizing is even more
complex: on one side, incomplete strut apposition
causes shear flow disturbances resulting in a delay in
adluminal neointimal coverage (22); on the other
side, classical fluid dynamic studies (23) demonstrate
that stent undersizing may result in an heteroge-
neous pattern of wall shear stress, which is associated
with both neointimal hyperplasia and thrombosis.
Data from the ABSORB cohort B show that the phys-
iological correction of malapposition involves neo-
intimal growth from the strut to the vessel wall
through a so-called “confluent model” (i.e., a prolif-
eration of endothelial cells from the injured vessel
wall to the surface of the stent). Both phenomena
might have contributed to the observed bimodal dis-
tribution of the risk of ScR for low and high values of
nominal or RVD ratio. The role of residual stenosis
and RVD as predictors of ScR is in line with findings
from drug-eluting stents (15–17).
With regard to the type of neointima, the most
common pattern was a high-intensity, homogeneous
tissue compatible with fibrotic, mature neointima.
CENTRAL ILLUSTRATION Description of the Concept of Vessel Size (RVD), Vessel Sizing (Relationship Between
Nominal Device Diameter and RVD)
Polimeni, A. et al. J Am Coll Cardiol Intv. 2017;10(18):1819–27.
The bottom left panel shows scaffold restenosis (ScR) as a function of bioresorbable coronary scaffold (BRS) sizing (nominal diameter/reference vessel diameter [RVD]).
(Toppanels)Undersizing (choiceof a BRS>9%smaller than theRVD,or nominal diameter/RVD<0.91) andoversizing (nominal diameter/RVD>1.13)werebothassociated
with increased risk of ScR. Oversizingmight lead to vessel trauma and increased strut density, which both stimulate proliferation. Undersizingmight lead to malapposition
and disruption in the laminarity of the flow, also a stimulus for neointima growth. The bottom right panel shows the incidence of ScR was also significantly higher for
vessels with RVD<2.7mm. Importantly, the incidence further increased for smaller RVD, showing a gradient in the risk of ScR with decreasing RVD. KM¼ Kaplan-Meier.
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1825Low-intensity areas (peristrut), possibly suggestive
of inflammatory reactions, were rarer. Although in
the absence of histological confirmation any
conclusion regarding the nature of these tissues
should be taken with caution, along with the
absence of features typical of neoatherosclerosis or
inflammatory reactions such as evaginations or
malappositions, uncovered struts, and microvessels,
and with mostly stable clinical presentation, these
data appear to be compatible with a progressive
growth of (benign) fibrotic neointima. Finally, the
more frequent presence of fractures in ScR is
compatible with the concept that fractures struts
might represent a mechanical stimulus for neointima
proliferation (24).
ROLE OF THE IMPLANTATION TECHNIQUE. Due to
the larger strut width and the resulting largerabluminal surface area, BRS exert a lower “pene-
trating” pressure at the time of implantation, which
might result in less embedment of struts in the vessel
wall, in turn leading to flow turbulence and lower
shear stress. This concept is compatible with our ev-
idence that an accurate implantation technique, ul-
timately aimed at optimizing both vessel and BRS
expansion, is associated with a reduction in ScR.
STUDY LIMITATIONS. The registry nature of this
study has clear inherent limitations, and although the
methods used for the acquisition and analysis of the
data were similar to those used in randomized
controlled trials, the evidence provided here should
be seen as hypothesis generating and exploratory. On
the other side, the absence of inclusion or exclusion
criteria and the complexity of the patients or lesions
treated here provide directly applicable information.
PERSPECTIVES
WHAT IS KNOWN? Data from randomized
controlled trials demonstrate a higher rate of target
lesion failure in patients treated with BRS as
compared with those treated with metal drug-eluting
stents.
WHAT IS NEW? We investigated the incidence,
clinical presentation, and predictors of clinical
restenosis (ScR) in a cohort of consecutive all-comer
patients. We found that the incidence of ScR is often
associated with a benign presentation and a complex
angiographic pattern. The technique used at the time
of implantation has a central role in reducing the
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1826Although an external independent laboratory was not
involved, QCA and OCT data were analyzed using
standard operating procedures by dedicated staff
otherwise independent of the study. As mentioned,
ScR is a multifactorial phenomenon in which vessel or
stent geometry, strut thickness, and a number of
patient or lesion or procedural characteristics play a
role. By including the American College of Cardiology
or American Heart Association classification as a
variable, we computed the sum of multiple variables
(e.g., lesion length, tortuosity, chronic total occlu-
sion, ostial location). Larger databases are necessary
to investigate each of these features. Because treat-
ment of calcific lesions and tortuous vessels or lesions
was discouraged or contraindicated from the begin-
ning, we do not have enough cases to run a separate
analysis for these endpoints. This “safety bias” did
not allow investigating a possible predictor of events
exactly because the risk of events was felt to be un-
acceptably high from the beginning. The absence of
an OCT assessment at the time of the implantation is
also a clear limitation, and the absence of routine
angiographic follow-up allows us to conclude on
clinical, but not angiographic, restenosis.incidence of ScR.
WHAT IS NEXT? Larger-scale direct comparative
trials with long-term follow-up and imaging are
required to better define the relative outcomes
between these devices.CONCLUSIONS
The 3-year incidence of ScR was similar to that
observed in similar settings with newer-generation
drug-eluting stents. ScR in BRS had mostly a benign
presentation but a complex angiographic pattern.The incidence of ScR was lower when an optimal
implantation technique was used.
ADDRESS FOR CORRESPONDENCE: Dr. Tommaso
Gori, Kardiologie I, Zentrum für Kardiologie,
University Medical Center Mainz, Langenbeckstrasse
1, 55131 Mainz, Germany. E-mail: tommaso.gori@
unimedizin-mainz.de.RE F E RENCE S1. Serruys PW, Chevalier B, Sotomi Y, et al. Com-
parison of an everolimus-eluting bioresorbable
scaffold with an everolimus-eluting metallic stent
for the treatment of coronary artery stenosis
(ABSORB II): a 3 year, randomised, controlled,
single-blind, multicentre clinical trial. Lancet
2016;388:2479–91.
2. Woudstra P, Grundeken MJ, Kraak RP, et al.
Amsterdam Investigator-initiateD Absorb strategy
all-comers trial (AIDA trial): a clinical evaluation
comparing the efficacy and performance of
ABSORB everolimus-eluting bioresorbable
vascular scaffold strategy vs the XIENCE family
(XIENCE PRIME or XIENCE Xpedition) everolimus-
eluting coronary stent strategy in the treatment of
coronary lesions in consecutive all-comers: ratio-
nale and study design. Am Heart J 2014;167:
133–40.
3. Polimeni A, Anadol R, Munzel T, Indolfi C,
De Rosa S, Gori T. Long-term outcome of
bioresorbable vascular scaffolds for the treat-
ment of coronary artery disease: a meta-
analysis of RCTs. BMC Cardiovasc Disord
2017;17:147.4. Stone GW, Gao R, Kimura T, et al. 1-year
outcomes with the Absorb bioresorbable
scaffold in patients with coronary artery disease:
a patient-level, pooled meta-analysis. Lancet
2016;387:1277–89.
5. Kallinikou Z, Arroyo D, Togni M, et al. Vascular
response to everolimus- and biolimus-eluting
coronary stents versus everolimus-eluting bio-
resorbable scaffolds–an optical coherence to-
mography substudy of the EVERBIO II trial. Swiss
Med Wkly 2016;146:w14274.
6. Raber L, Onuma Y, Brugaletta S, et al. Arterial
healing following primary PCI using the Absorb
everolimus-eluting bioresorbable vascular scaffold
(Absorb BVS) versus the durable polymer
everolimus-eluting metallic stent (XIENCE) in
patients with acute ST-segment elevation
myocardial infarction: rationale and design of the
randomised TROFI II study. EuroIntervention
2016;12:482–9.
7. Puricel S, Cuculi F, Weissner M, et al. Bio-
resorbable coronary scaffold thrombosis: multi-
center comprehensive analysis of clinicalpresentation, mechanisms, and predictors. J Am
Coll Cardiol 2016;67:921–31.
8. Cutlip DE, Windecker S, Mehran R, et al. Clinical
end points in coronary stent trials: a case for
standardized definitions. Circulation 2007;115:
2344–51.
9. Gori T, Schulz E, Hink U, et al. Clinical,
angiographic, functional, and imaging outcomes
12 months after implantation of drug-eluting
bioresorbable vascular scaffolds in acute coro-
nary syndromes. J Am Coll Cardiol Intv 2015;8:
770–7.
10. Gori T, Jansen T, Weissner M, et al. Coronary
evaginations and peri-scaffold aneurysms
following implantation of bioresorbable scaffolds:
incidence, outcome, and optical coherence to-
mography analysis of possible mechanisms. Eur
Heart J 2016;37:2040–9.
11. Gori T, Wiebe J, Capodanno D, et al. Early and
midterm outcomes of bioresorbable vascular
scaffolds for ostial coronary lesions: insights from
the GHOST-EU registry. EuroIntervention 2016;11:
e550–6.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 0 , N O . 1 8 , 2 0 1 7 Polimeni et al.
S E P T E M B E R 2 5 , 2 0 1 7 : 1 8 1 9 – 2 7 Bioresorbable Vascular Scaffolds Restenosis
182712. Song L, Mintz GS, Yin D, et al. Characteristics
of early versus late in-stent restenosis in second-
generation drug-eluting stents: an optical coher-
ence tomography study. EuroIntervention 2017;13:
294–302.
13. Harrell FE Jr., Lee KL, Califf RM, Pryor DB,
Rosati RA. Regression modelling strategies for
improved prognostic prediction. Stat Med 1984;3:
143–52.
14. Indolfi C, De Rosa S, Colombo A. Bioresorbable
vascular scaffolds - basic concepts and clinical
outcome. Nat Rev Cardiol 2016;13:719–29.
15. Kastrati A, Schomig A, Elezi S, et al. Predictive
factors of restenosis after coronary stent place-
ment. J Am Coll Cardiol 1997;30:1428–36.
16. Abizaid A, Kornowski R, Mintz GS, et al. The
influence of diabetes mellitus on acute and late
clinical outcomes following coronary stent im-
plantation. J Am Coll Cardiol 1998;32:584–9.
17. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M,
Dirschinger J, Schomig A. Vessel size and long-
term outcome after coronary stent placement.
Circulation 1998;98:1875–80.18. Indolfi C, Mongiardo A, Spaccarotella C,
Caiazzo G, Torella D, De Rosa S. Neointimal pro-
liferation is associated with clinical restenosis 2
years after fully bioresorbable vascular scaffold
implantation. Circ Cardiovasc Imaging 2014;7:
755–7.
19. Gomez-Lara J, BrugalettaS, FarooqV, et al. Head-
to-head comparison of the neointimal response be-
tween metallic and bioresorbable everolimus-eluting
scaffolds using optical coherence tomography. J Am
Coll Cardiol Intv 2011;4:1271–80.
20. Bourantas CV, Papafaklis MI, Kotsia A, et al.
Effect of the endothelial shear stress patterns on
neointimal proliferation following drug-eluting
bioresorbable vascular scaffold implantation: an
optical coherence tomography study. J Am Coll
Cardiol Intv 2014;7:315–24.
21. Colombo A. Influence of residual stenosis after
coronary stent implantation on development of
restenosis and stent thrombosis. Am J Cardiol
2003;92:1013.
22. Gutierrez-Chico JL, Gijsen F, Regar E, et al.
Differences in neointimal thickness between theadluminal and the abluminal sides of malapposed
and side-branch struts in a polylactide bio-
resorbable scaffold: evidence in vivo about the
abluminal healing process. J Am Coll Cardiol Intv
2012;5:428–35.
23. Chen HY, Hermiller J, Sinha AK, Sturek M,
Zhu L, Kassab GS. Effects of stent sizing on
endothelial and vessel wall stress: potential
mechanisms for in-stent restenosis. J Appl Physiol
2009;106:1686–91.
24. Omar A, Pendyala LK, Ormiston JA,
Waksman R. Review: stent fracture in the drug-
eluting stent era. Cardiovasc Revasc Med 2016;
17:404–11.KEY WORDS bioresorbable scaffolds,
optical coherence tomography, restenosis
APPENDIX For expanded Methods and
references sections as well as supplemental
tables, please see the online version of this
article.
